Incyte Corporation (INCY) Analysts See $0.19 EPS

October 16, 2018 - By Hugh Holland

Incyte Corporation (NASDAQ:INCY) LogoInvestors sentiment increased to 1.23 in 2018 Q2. Its up 0.01, from 1.22 in 2018Q1. It increased, as 73 investors sold Incyte Corporation shares while 101 reduced holdings. 52 funds opened positions while 162 raised stakes. 183.44 million shares or 3.60% less from 190.28 million shares in 2018Q1 were reported.
Neuberger Berman Grp Limited Liability stated it has 0.03% in Incyte Corporation (NASDAQ:INCY). Texas-based Employees Retirement Sys Of Texas has invested 0.06% in Incyte Corporation (NASDAQ:INCY). Signaturefd Ltd invested in 514 shares or 0% of the stock. Los Angeles Capital Mgmt & Equity Rech has invested 0.02% in Incyte Corporation (NASDAQ:INCY). Dafna Mgmt Limited Liability Corp holds 0.67% or 21,500 shares. 26,831 were reported by Mirae Asset Investments Co Ltd. Weiss Multi has 0.06% invested in Incyte Corporation (NASDAQ:INCY). 41,419 are held by Sabby Mngmt Limited Liability Company. Sands Capital Mngmt Limited Com holds 0.92% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 4.77M shares. Verition Fund Management Ltd Limited Liability Company reported 20,377 shares. The California-based Capital Intll Sarl has invested 1.15% in Incyte Corporation (NASDAQ:INCY). Metropolitan Life Ny stated it has 35,206 shares or 0% of all its holdings. 9,435 are held by Public Sector Pension Inv Board. Sg Americas Secs Limited Company invested 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY). Sit Inv Inc invested in 22,975 shares or 0.04% of the stock.

Since April 30, 2018, it had 1 buy, and 5 insider sales for $6.27 million activity. 606 shares valued at $43,232 were sold by Iyengar Vijay K on Monday, July 9. Hoppenot Herve bought $914,100 worth of stock or 15,000 shares.

Analysts expect Incyte Corporation (NASDAQ:INCY) to report $0.19 EPS on October, 30.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $0.17 EPS. INCY’s profit would be $40.39M giving it 81.62 P/E if the $0.19 EPS is correct. After having $0.13 EPS previously, Incyte Corporation’s analysts see 46.15 % EPS growth. The stock decreased 0.85% or $0.53 during the last trading session, reaching $62.03. About 835,653 shares traded. Incyte Corporation (NASDAQ:INCY) has declined 45.99% since October 16, 2017 and is downtrending. It has underperformed by 61.61% the S&P500.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 11 analysts covering Incyte Corp (NASDAQ:INCY), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Incyte Corp had 14 analyst reports since April 23, 2018 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Tuesday, April 24. The firm has “Buy” rating by Piper Jaffray given on Wednesday, May 30. The firm earned “Buy” rating on Friday, June 15 by Piper Jaffray. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Friday, July 13 report. The rating was upgraded by RBC Capital Markets to “Outperform” on Wednesday, August 15. SunTrust maintained Incyte Corporation (NASDAQ:INCY) rating on Monday, April 23. SunTrust has “Buy” rating and $7500 target. The firm has “Overweight” rating given on Thursday, May 31 by PiperJaffray. JMP Securities downgraded the shares of INCY in report on Wednesday, August 1 to “Market Perform” rating. The firm has “Perform” rating given on Wednesday, July 18 by Oppenheimer. The firm earned “Hold” rating on Tuesday, May 1 by Oppenheimer.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $13.19 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It currently has negative earnings. The company??s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: Globenewswire.com which released: “Report: Developing Opportunities within Packaging Corporation of America, Jones Energy, Pitney Bowes, Mercury …” on October 12, 2018, also Fool.com with their article: “3 Top Biotech Stocks to Buy in October” published on October 08, 2018, Seekingalpha.com published: “Key events next week – healthcare” on October 12, 2018. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on October 01, 2018 as well as Schaeffersresearch.com‘s news article titled: “2 Healthcare Stocks That Could Bounce Back Next Week” with publication date: October 12, 2018.

Incyte Corporation (NASDAQ:INCY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>